-
A program in Seattle is helping people in drug and alcohol recovery overcome barriers to medical care in an effort to keep them off the street. A key piece is battling stigma from medical providers.
-
Indivior was accused of using illegal strategies to keep generic versions of the opioid-treatment medication Suboxone off the market. Several states, including Florida, sued the company, which denies wrongdoing.
-
This episode is devoted to a conversation with Dr. Nancy Diazgranados, deputy clinical director of the National Institute on Alcohol Abuse and Alcoholism.
-
A few dozen high schools across the U.S. combine education with treatment for substance use disorders to keep kids in recovery — and in school.
-
Research shows that a “housing first” approach benefits individuals and families facing chronic homelessness and those with long-standing mental illness or substance use disorders.
-
Federal restrictions seemed to explain why many doctors weren't prescribing medication for opioid addiction. But some caution that removing those rules isn't enough to overcome hesitancy and stigma.
-
The veterinary tranquilizer xylazine, the choice du jour of local drug dealers to cut fentanyl, leads to necrotic ulcers and leaves street medics and physicians confused about how best to deal with this wave of the opioid crisis.
-
Private equity groups are cashing in on rising rates of alcohol and drug addiction in the U.S. But they aren’t necessarily investing in centers with the best treatment standards, and they often cut extra services.
-
During the time that deaths from addiction and suicide among white Americans rose by about 9%, deaths among Native Americans shot up by about 30%, a new study shows.
-
Xylazine, an animal tranquilizer, is increasingly finding its way into street drugs across the country. Analysts at New Hampshire's state crime lab estimate they’re finding it in about 15% of the fentanyl they test.